N,N-dimethyl-glutaric diamide | 89941-01-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N-dimethyl-glutaric diamide
• 英文别名: N.N-Dimethyl-glutarsaeure-diamid；N~1~,N~1~-Dimethylpentanediamide；N',N'-dimethylpentanediamide
• CAS: 89941-01-5
• 化学式: C₇H₁₄N₂O₂
• 分子量: 158.2
• InChiKey: PSLBHYDGBUDCNI-UHFFFAOYSA-N

物化性质

• 熔点：
  97-98 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  363.1±25.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  63.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-酮丁酸 、 N,N-dimethyl-glutaric diamide 以 甲苯 为溶剂， 以26%的产率得到(Z)-2-[[5-(dimethylamino)-5-oxopentanoyl]amino]but-2-enoic acid
  参考文献：
  名称：

  Inhibition of the mammalian .beta.-lactamase renal dipeptidase (dehydropeptidase-I) by Z-2-(acylamino)-3-substituted-propenoic acids

  摘要：

  The title enzyme deactivates the potent carbapenem antibiotic imipenem in the kidney, producing low antibiotic levels in the urinary tract. A series of (Z)-2-(acylamino)-3-substituted-propenoic acids (3) are specific, competitive inhibitors of the enzyme capable of increasing the urinary concentration of imipenem in vivo. Many of the compounds were prepared in one step from an alpha-keto acid and a primary amide. The optimum R2 groups are 2,2-dimethyl, -dichloro, and -dibromocyclopropyl. With R2 = 2,2-dimethylcyclopropyl (DMCP), a wide variety of R3 groups including alkyl, oxa- and thiaalkyl, and alkyl groups containing acidic, basic, and neutral substituents give effective inhibitors with Ki values of 0.02-1 microM and a range of pharmacokinetic properties. By resolution of enantiomers and X-ray crystallography, the enzyme-inhibitory activity of the DMCP group was found to reside with the 1S isomer. The cysteinyl compound 176 (cilastatin, MK-0791) has the desired pharmacological properties and has been chosen for combination with imipenem.

  DOI：

  10.1021/jm00389a018
• 作为产物：
  描述：

  5-(dimethylamino)-5-oxopentanoic acid 在 氯化亚砜 、 氰化钠 、 氨 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 N,N-dimethyl-glutaric diamide
  参考文献：
  名称：

  的构象Ñ α在CDCl -取代肼乙酰胺3，Δδ的酰胺将氢之间的分析的珍贵的帮助，和相关到的构象氮杂β 3 -肽

  摘要：

  我们研究了氯仿溶液中一系列伯酰胺的构象。将经典的NMR工具（例如稀释实验，DMSO和2D-NOESY的影响）与X射线衍射相结合，并分析了双键mid质子之间化学位移Δδ的差异。本研究中为了理解由肼基乙酰胺采用的构象是写给1A和1B作为模型化合物为氮杂- β 3-肽。以这种方式，有可能表明这些化合物的酰胺基充当氢键供体并与两个不同的氢键受体相互作用。我们得出的结论是，肼苯二酚，一种在固态下观察到的特定的分叉H键系统，也是溶液中肼基乙酰胺1a和1b的优选构象。我们的研究结果表明，与所述短距离相互作用Ñ α -氮的孤对电子不仅稳定C8 pseudocycle但也可能有助于氮杂- β的折叠处理3 -肽。鉴于此，它可以解释为什么氮杂β 3 -肽发展比较不同的氢键网络，其等量β 3-肽类似物。我们的工作与肼基肽作为β肽概念的扩展的最新兴趣保持一致。

  DOI：

  10.1021/jo051887q

文献信息

• Quantitative Solid-State Reactions of Amines with Carbonyl Compounds and Isothiocyanates
  作者：Gerd Kaupp、Jens Schmeyers、Juergen Boy

  DOI：10.1016/s0040-4020(00)00511-1

  日期：2000.9

  solid anhydrides to give diamides (therefrom imides) or amidic carboxylic salts or imides, with solid imides to give diamides, with solid lactones or carbonates to give functionalized carbamic esters, with polycarbonates to give degradative aminolysis, and with solid isothiocyanates to give thioureas. Diamides give imides by solid-state thermolysis or acid catalysis. Various double, two-step, 3-cascade

  据报道，气态或固态胺与醛的一系列固相反应生成亚胺，固态酸酐生成二酰胺（由酰亚胺生成）或酰胺羧酸盐或酰亚胺，固态酰亚胺生成二酰胺，与固态内酯或碳酸盐生成固态反应。得到官能化的氨基甲酸酯，与聚碳酸酯得到降解的氨解，和与固体异硫氰酸酯得到硫脲。二酰胺通过固态热解或酸催化作用生成酰亚胺。据报道，各种双反应，两步反应，3级反应和顺序反应均处于固态而不熔化。在53个已报告的反应实例中，产率是定量的，并且在100％产率的反应中无需进行后处理（除了四次洗涤）。最初的三个固态反应但与液态产物的反应不是定量的。升至公斤级显示了该技术在大规模应用中的前景。原子力显微镜的超显微分析通过三步法中影响深远的各向异性分子运动阐明了固态机制。还使用AFM研究了聚碳酸酯的气固氨基分解酶。讨论了对可持续化学的影响。
• Quinazoline derivatives
  申请人：ZENECA LIMITED

  公开号：EP0566226A1

  公开（公告）日：1993-10-20

  The invention concerns quinazoline derivatives of the formula I wherein m is 1, 2 or 3 and each R1 includes hydroxy, amino, carboxy, carbamoyl, ureido, (1-4C)alkoxycarbonyl, N-(1-4C)alkylcarbamoyl, N,N-di-[(1-4C)alkyl]carbamoyl, hydroxyamino, (1-4C)alkoxyamino, (2-4C)alkanoyloxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)al- kylenedioxy ; n is 1 or 2 and each R2 includes hydrogen, hydroxy, halogeno, trifluoromethyl, amino, nitro, cyano and (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof; processes for their preparation ; pharmaceutical compositions containing them ; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.

  本发明涉及式 I 的喹唑啉衍生物 其中m为1、2或3，每个R1包括羟基、氨基、羧基、氨基甲酰基、脲基、(1-4C)烷氧基羰基、N-(1-4C)烷基氨基甲酰基、N,N-二[(1-4C)烷基]氨基甲酰基、羟基氨基、(1-4C)烷氧基氨基、(2-4C)烷酰氧基氨基、三氟甲氧基、(1-4C)烷基、(1-4C)烷氧基和(1-3C)烷二氧基； n 为 1 或 2，每个 R2 包括氢、羟基、卤素、三氟甲基、氨基、硝基、氰基和 (1-4C) 烷基； 或其药学上可接受的盐； 它们的制备工艺；含有它们的药物组合物；以及利用这些化合物的受体酪氨酸激酶抑制特性治疗癌症。
• Conformation-directing effects of a single intramolecular amide-amide hydrogen bond: variable-temperature NMR and IR studies on a homologous diamide series
  作者：Samuel H. Gellman、Gregory P. Dado、Gui Bai Liang、Bruce R. Adams

  DOI：10.1021/ja00004a016

  日期：1991.2

  We have studied intramolecular hydrogen bonding in a homologous series of diamides (compounds 1-6) in methylene chloride, 9:1 carbon tetrachloride/benzene, and acetonitrile. By correlating variable-temperature H-1 NMR and IR measurements, we have shown that the temperature dependence of the amide proton NMR chemical shift (DELTA-delta/DELTA-T) can provide qualitative (and in some cases quantitative) information on the thermodynamic relationship between the intramolecularly hydrogen bonded and non-hydrogen-bonded states of flexible molecules. Among the hydrogen-bonded ring sizes represented in the diamide series, the intramolecular interaction is particularly enthalpically favorable in the nine-membered hydrogen-bonded ring (compound 4). Variable-temperature IR and NMR data indicate that the internally hydrogen bonded state of diamide 4 is 1.4-1.6 kcal/mol more favorable enthalpically than the non-hydrogen-bonded state, in methylene chloride solution; the non-hydrogen-bonded state is 6.8-8.3 eu more favorable entropically in this solvent. In contrast, there appear to be much smaller enthalpy differences between the internally hydrogen bonded and non-hydrogen-bonded states of diamides 2 and 3. Our findings are important methodologically because the temperature dependences of amide proton chemical shifts are commonly used to elucidate peptide conformation in solution. Our results show that previous "rules" for the interpretation of such data are incomplete. In non-hydrogen-bonding solvents, small amide proton DELTA-delta/DELTA-T values have been taken to mean that the proton is either entirely free of hydrogen bonding or completely locked in an intramolecular hydrogen bond over the temperature range studied. We demonstrate that an amide proton can be equilibrating between intramolecularly hydrogen bonded and non-hydrogen-bonded states and still manifest a small chemical shift temperature dependence (implying that the hydrogen-bonded and non-hydrogen-bonded states are of similar enthalpy).
• Single particle electrochemical sensors and methods of utilization
  申请人：——

  公开号：US20030211637A1

  公开（公告）日：2003-11-13

  The present invention discloses an electrochemical device for detecting single particles, and methods for using such a device to achieve high sensitivity for detecting particles such as bacteria, viruses, aggregates, immuno-complexes, molecules, or ionic species. The device provides for affinity-based electrochemical detection of particles with single-particle sensitivity. The disclosed device and methods are based on microelectrodes with surface-attached, affinity ligands (e.g., antibodies, combinatorial peptides, glycolipids) that bind selectively to some target particle species. The electrodes electrolyze chemical species present in the particle-containing solution, and particle interaction with a sensor element modulates its electrolytic activity. The devices may be used individually, employed as sensors, used in arrays for a single specific type of particle or for a range of particle types, or configured into arrays of sensors having both these attributes.
• AMINOPYRAZOLONE DERIVATIVE
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20170107207A1

  公开（公告）日：2017-04-20

  The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which has an excellent inhibitory action on the ATPase activity of a TIP48/TIP49 complex and as such, is useful for the treatment of tumors. [Solution] The present invention provides a compound having a structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and W are as defined in the present specification.